NSC697923
Ubiquitin E2 Conjugating enzyme inhibitor / Selective inhibitor of E2 ubiquitin-conjugating enzyme, Ubc13-Uev1A. Does not inhibit UbcH5c activity. Impedes the formation of the Ubc13 and inhibits NF-κB activation in activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cells1. Blocks proliferation and survival of both ABC-DLBCL and germinal center B cell-like (GCB)-DLBCL cell lines, and survival of primary DLBCL cells. Acts via covalent bonding to E2 active site thiol2,3. Induces neuroblastoma cell death via activation of p53 and JNK4.
Biochemicals & reagents
343351-67-7
1) Pulvino et al. (2012), Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A; Blood, 120 1668 2) Strickson et al. (2013), the anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system; Biochem. J., 451 427 3) Hodge et al. (2015), Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting; ACS Chem. Biol. 10 1718 4) Cheng et al. (2014), A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways; Cell Death Dis., 5 e1079
-20°C
TARGET: UBC (ubiquitin conjugating enzyme) -- PATHWAY: Degradation; NFkappaB; Proliferation; JNK pathway; p53; Apoptosis inducer -- RESEARCH AREA: Ubiquitin/Proteasome; Cell death